UNASSIGNED: e15519 Background: Ovarian @entity5 is the most lethal gynecologic malignancy in the United States. Initial treatment for advanced stage disease is @entity902 -based chemotherapy. While a majority of @entity43 cases are initially chemo-sensitive, most @entity1 will recur and ultimately succumb to their disease. Recurrent @entity5 eventually become chemo-resistant, with effective anti-neoplastic agents limited. Premetrexed is an antifolate agent which has shown activity as a single agent several different @entity5 . The goal of our study was to review the efficacy of Premetrexed in @entity1 with recurrent @entity43 . METHODS: @entity1 with recurrent @entity43 who were treated with premetrexed at Roswell Park @entity5 Institute were identified. The efficacy of treatment, based on @entity10224 response and duration of therapy was assessed. Premetrexed was administered as a single agent at a dose of 500 mg/m(2) every 21 days. RESULTS: Fourteen @entity1 met inclusion criteria. Ten @entity1 (71%) had a decrease in their @entity10224 value while on premetrexed. The mean number of cycles administered in this group was 6.7 (range, 3 to 17). Four @entity1 (29%) had progressive disease as manifested by an increasing @entity10224 while receiving premetrexed. The mean number of cycles was 3.25 (range, 3 to 4). The mean number of prior cytotoxic regimens for all @entity1 was 7.3 courses. CONCLUSIONS: Premetrexed is a viable treatment option, capable of durable responses, in heavily pretreated @entity1 with recurrent @entity43 .

Evaluation of the role of premetrexed in the treatment of refractory, recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'epithelial ovarian or peritoneal cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer', 'cancer', 'malignancies', 'tumors'] @entity10224 :: ('94025', 'Gene') :: ['CA125'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity43 :: (MESH:D010051,Disease) :: ['epithelial ovarian cancer']
